[Renal cell carcinomas. Pathomorphologic diagnosis in the light of modern pharmacotherapy].
Renal carcinomas have been classified with increasing accuracy in recent years and new sub-groups have been assigned, which, due to their distinct development pathways, carry varying prognoses and require specific treatment approaches. A range of antibodies are available for their immunohistochemical classification. Identifying a gene defect--mutation, deletion, trisomies and monosomies, oncogene activation--enables the application of targeted therapy, e.g. using antibodies or tyrosine kinase inhibitors in signaling pathways, among others. Renal carcinoma diagnosis by the pathologist is taking on a particularly important role.
Störkel
S
S
Institut für Pathologie der UWH, Helios-Klinikum Wuppertal, Heusnerstrasse 40, Wuppertal. stephan.stoerkel@helios-kliniken.de
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D004252:DNA Mutational Analysis; D016503:Drug Delivery Systems; D006801:Humans; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D025202:Molecular Diagnostic Techniques; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011505:Protein-Tyrosine Kinases